Use of an anti-CD20 type II antibody with increased antibody-dependent cellular cytotoxicity (ADCC) in combination with cyclophosphamide, vincristine and doxorubicin for the treatment of non-Hodgkin lymphomas

摘要

Use of an anti-CD20 type II antibody with increased antibody-dependent cellular cytotoxicity (ADCC) for the preparation of a medicament for the treatment of cancer expressing CD20 in combination with one or more chemotherapeutic agents selected from the group consisting of cyclophosphamide, vincristine and doxorubicin, characterized in that said type II anti-CD20 antibody is a glucomanipulated humanized B-Ly1 antibody in which the humanized B-Ly1 antibody has the heavy chain variable region (VH) of SEQ ID No. 7 and a variable region of the light chain (VL) of SEQ ID No. 20 and treatment with the anti-CD20 type II antibody is performed in combination a) with cyclophosphamide and vincristine, or b) cyclophosphamide, vincristine and doxorubicin.